Zoetis Inc. (NYSE:ZTS)‘s stock had its “hold” rating reaffirmed by equities research analysts at BMO Capital Markets in a research note issued to investors on Thursday, November 2nd. They presently have a $65.00 target price on the stock. BMO Capital Markets’ price target suggests a potential downside of 5.63% from the stock’s previous close.
A number of other research firms have also recently commented on ZTS. Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the stock a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus reissued a “buy” rating and set a $65.00 price target on shares of Zoetis in a report on Friday, September 1st. Deutsche Bank AG restated a “buy” rating and set a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research report on Monday, July 17th. BidaskClub lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Finally, Zacks Investment Research lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the stock. Zoetis has a consensus rating of “Buy” and a consensus price target of $67.06.
Zoetis (NYSE ZTS) opened at $68.88 on Thursday. The firm has a market capitalization of $33,686.24, a price-to-earnings ratio of 31.71, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a fifty-two week low of $48.24 and a fifty-two week high of $70.48.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the previous year, the firm earned $0.52 EPS. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. equities research analysts anticipate that Zoetis will post 2.36 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.truebluetribune.com/2017/11/14/zoetis-zts-hold-rating-reiterated-at-bmo-capital-markets.html.
Several institutional investors have recently modified their holdings of ZTS. Northwestern Mutual Wealth Management Co. raised its stake in shares of Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the last quarter. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Zoetis in the first quarter worth approximately $111,000. Harfst & Associates Inc. raised its stake in shares of Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the last quarter. Almanack Investment Partners LLC. purchased a new stake in shares of Zoetis in the second quarter worth approximately $119,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the last quarter. 92.44% of the stock is owned by hedge funds and other institutional investors.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.